Honigberg MC, Chang LS, McGuire DK, Plutzky J, Aroda VR, Vaduganathan M
With injections, you get the drug once a week
In January of this year, the FDA noted that it had "received adverse event reports after patients used compounded semaglutide" and that "patients should not use a compounded drug if an approved drug is available to treat a patient." In July, the agency followed up with a notice that it had "received reports of adverse events, some requiring hospitalization, that may be related to overdoses due to dosing errors associated with compounded semaglutide injectable products." And in August, Eli Lilly, the maker of Zepbound and Mounjaro, sent a series of cease-and-desist letters to providers urging them to stop prescribing compounded versions of those drugs
Exploring the impact of sodium-glucose cotransporter-2 inhibitors on genitourinary toxicities in prostate cancer patients undergoing radiation therapy: a case study and discussion
A structured reset with a different formulation or dosing strategy sometimes restores responsiveness
Those who stayed on the medication the entire time lost about 17%